TP53 and endometrioid adenocarcinoma: Mutation-type p53 immunostaining serves as an indicator of the Cancer Genome Atlas (TCGA)-based molecular subtype of endometrioid carcinoma with the worst prognosis, especially when applied as part of a diagnostic algorithm 1,2.